A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy
Status:
Withdrawn
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label, dose-escalating Phase Ia study performed at a single
center designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of
intravitreous administration of RNA-144101 in patients with geographic atrophy (GA).